keyword
https://read.qxmd.com/read/38444199/comparison-of-the-oncolytic-activity-of-a-replication-competent-and-a-replication-deficient-herpes-simplex-virus-1
#1
JOURNAL ARTICLE
Georg Lindner, Annika Walter, Clara L Magnus, Katharina Rosenhammer, Bohdan Holoborodko, Victoria Koch, Sarah Hirsch, Luis Grossmann, Suqi Li, David M Knipe, Neal DeLuca, Beatrice Schuler-Thurner, Stefanie Gross, Barbara Schwertner, Martina Toelge, Anette Rohrhofer, Sabine Stöckl, Richard J Bauer, Gertrud Knoll, Martin Ehrenschwender, Sebastian Haferkamp, Barbara Schmidt, Philipp Schuster
In 2015, the oncolytic herpes simplex virus 1 (HSV-1) T-VEC (talimogene laherparepvec) was approved for intratumoral injection in non-resectable malignant melanoma. To determine whether viral replication is required for oncolytic activity, we compared replication-deficient HSV-1 d106S with replication-competent T-VEC. High infectious doses of HSV-1 d106S killed melanoma (n = 10), head-and-neck squamous cell carcinoma (n = 11), and chondrosarcoma cell lines (n = 2) significantly faster than T-VEC as measured by MTT metabolic activity, while low doses of T-VEC were more effective over time...
March 5, 2024: Immunology
https://read.qxmd.com/read/38435173/hiv-encoded-gene-therapy-as-anti-cancer-therapeutics-a-narrative-review
#2
REVIEW
Pachamuthu Balakrishnan, Sankar Sathish, Shanmugam Saravanan
Recently, there has been interest in using viruses as cancer treatments. Oncolytic virology was founded by scientists who noticed that viruses might preferentially lyse cancer cells over healthy ones. Oncolytic virotherapy has similar obstacles as other treatment approaches, gaining entry into the specific tumour cell, encountering antiviral immune responses, off-target infection and many other unfavourable circumstances in the tumour microenvironment, and a lack of unique therapeutic and predictive biomarkers...
February 2024: Curēus
https://read.qxmd.com/read/38224076/clinical-and-histological-response-to-talimogene-laherparepvec-therapy-in-advanced-melanoma-impact-on-overall-survival
#3
JOURNAL ARTICLE
Gabriel O Ologun, C Paige Jones, Kelsey R Landrum, P Veronica Pham, Sherin Ismail, Patricia K Long, Jonathan D Sorah, Karyn B Stitzenberg, Michael O Meyers, David W Ollila
BACKGROUND: Talimogene Laherparepvec (T-VEC) is an FDA-approved oncolytic herpes virus therapy used for unresectable stage IIIB through IV metastatic melanoma. However, the correlation between clinical complete response (cCR) and pathologic complete response (pCR) in T-VEC-treated patients is understudied. STUDY DESIGN: We conducted a retrospective study from a prospectively maintained IRB-approved melanoma single center database in patients treated with T-VEC from October 2015 to April 2022...
January 15, 2024: Journal of the American College of Surgeons
https://read.qxmd.com/read/38171406/advances-and-prospects-of-mrna-vaccines-in-cancer-immunotherapy
#4
REVIEW
Yixuan Liu, Qijia Yan, Zhaoyang Zeng, Chunmei Fan, Wei Xiong
Cancer vaccines, designed to activate the body's own immune system to fight against tumors, are a current trend in cancer treatment and receiving increasing attention. Cancer vaccines mainly include oncolytic virus vaccine, cell vaccine, peptide vaccine and nucleic acid vaccine. Over the course of decades of research, oncolytic virus vaccine T-VEC, cellular vaccine sipuleucel-T, various peptide vaccines, and DNA vaccine against HPV positive cervical cancer have brought encouraging results for cancer therapy, but are losing momentum in development due to their respective shortcomings...
January 1, 2024: Biochimica et Biophysica Acta. Reviews on Cancer
https://read.qxmd.com/read/38028532/editorial-oncolytic-virotherapy
#5
EDITORIAL
Ahmed Majeed Al-Shammari, Pier Paolo Piccaluga
No abstract text is available yet for this article.
2023: Frontiers in Molecular Biosciences
https://read.qxmd.com/read/38004669/attenuated-replication-competent-herpes-simplex-virus-expressing-an-ecm-modifying-transgene-hyaluronan-synthase-2-of-naked-mole-rat-in-oncolytic-gene-therapy
#6
JOURNAL ARTICLE
Jussi Palomäki, Kiira Kalke, Julius Orpana, Liisa Lund, Fanny Frejborg, Henrik Paavilainen, Hannu Järveläinen, Veijo Hukkanen
Herpes simplex virus (HSV) has proven successful in treating human cancer. Since the approval of talimogene laherparepvec (T-VEC) in 2015, HSV has been thoroughly researched to discover novel mechanisms to combat cancer and treat other diseases. Another HSV-based drug, beremagene geperpavec (B-VEC), received approval in 2023 to treat the rare genetic disease dystrophic epidermolysis bullosa, and was also the first clinically approved HSV vector carrying an extracellular matrix (ECM)-modifying transgene. The ECM is a network of macromolecules surrounding cells, which provides support and regulates cell growth and differentiation, the disruption of which is common in cancer...
October 29, 2023: Microorganisms
https://read.qxmd.com/read/37919738/the-efficacy-and-safety-assessment-of-oncolytic-virotherapies-in-the-treatment-of-advanced-melanoma-a-systematic-review-and-meta-analysis
#7
JOURNAL ARTICLE
Changyuan Wang, Nanxiao Lu, Lin Yan, Yang Li
BACKGROUND: The efficacy and safety of oncolytic virotherapies in the treatment of advanced melanoma still remains controversal. It is necessary to conduct quantitative evaluation on the basis of preclinical trial reports. METHODS: Publicly available databases (PubMed, Embase, Medline, Web of Science and Cochrane Library.) and register (Clinicaltrials.gov) were searched to collect treatment outcomes of oncolytic virotherapies (including herpes simplex virus type 1 (HSV), coxsackievirus A21 (CVA21), adenovirus, poxvirus and reovirus) for advanced/unresectable melanoma...
November 2, 2023: Virology Journal
https://read.qxmd.com/read/37891570/the-potential-of-swine-pseudorabies-virus-attenuated-vaccine-for-oncolytic-therapy-against-malignant-tumors
#8
JOURNAL ARTICLE
Guosong Wang, Jiali Cao, Mengxuan Gui, Pengfei Huang, Liang Zhang, Ruoyao Qi, Ruiqi Chen, Lina Lin, Qiangyuan Han, Yanhua Lin, Tian Chen, Peiqing He, Jian Ma, Rao Fu, Junping Hong, Qian Wu, Hai Yu, Junyu Chen, Chenghao Huang, Tianying Zhang, Quan Yuan, Jun Zhang, Yixin Chen, Ningshao Xia
BACKGROUND: Oncolytic viruses are now well recognized as potential immunotherapeutic agents against cancer. However, the first FDA-approved oncolytic herpes simplex virus 1 (HSV-1), T-VEC, showed limited benefits in some patients in clinical trials. Thus, the identification of novel oncolytic viruses that can strengthen oncolytic virus therapy is warranted. Here, we identified a live-attenuated swine pseudorabies virus (PRV-LAV) as a promising oncolytic agent with broad-spectrum antitumor activity in vitro and in vivo...
October 27, 2023: Journal of Experimental & Clinical Cancer Research: CR
https://read.qxmd.com/read/37795219/biosafety-and-biohazard-considerations-of-hsv-1-based-oncolytic-viral-immunotherapy
#9
REVIEW
Elizabeth Robilotti, Nathalie C Zeitouni, Marlana Orloff
Oncolytic viral immunotherapies are agents which can directly kill tumor cells and activate an immune response. Oncolytic viruses (OVs) range from native/unmodified viruses to genetically modified, attenuated viruses with the capacity to preferentially replicate in and kill tumors, leaving normal tissue unharmed. Talimogene laherparepvec (T-VEC) is the only OV approved for patient use in the United States; however, during the last 20 years, there have been a substantial number of clinical trials using OV immunotherapies across a broad range of cancers...
2023: Frontiers in Molecular Biosciences
https://read.qxmd.com/read/37711513/liver-transplant-patient-with-in-transit-squamous-cell-carcinoma-treated-with-talimogene-laherparepvec
#10
Jamie Lebhar, Jennifer Jacobs, Khushnood Faraz, April K S Salama, Paul J Mosca
No abstract text is available yet for this article.
October 2023: JAAD Case Reports
https://read.qxmd.com/read/37675296/combination-strategies-incorporating-oncolytic-viruses-and-immune-checkpoint-inhibitors-for-advanced-melanoma-what-is-the-evidence
#11
EDITORIAL
Amarin Wongariyapak, Victoria Roulstone, Alan A Melcher, Malin Pedersen, Kevin J Harrington
No abstract text is available yet for this article.
August 30, 2023: Annals of Translational Medicine
https://read.qxmd.com/read/37629523/new-treatment-horizons-in-uveal-and-cutaneous-melanoma
#12
REVIEW
Daciana Elena Brănişteanu, Elena Porumb-Andrese, Vlad Porumb, Alexandra Stărică, Andreea Dana Moraru, Alin Codruț Nicolescu, Mihail Zemba, Cătălina Ioana Brănişteanu, George Brănişteanu, Daniel Constantin Brănişteanu
Melanoma is a complex and heterogeneous malignant tumor with distinct genetic characteristics and therapeutic challenges in both cutaneous melanoma (CM) and uveal melanoma (UM). This review explores the underlying molecular features and genetic alterations in these melanoma subtypes, highlighting the importance of employing specific model systems tailored to their unique profiles for the development of targeted therapies. Over the past decade, significant progress has been made in unraveling the molecular and genetic characteristics of CM and UM, leading to notable advancements in treatment options...
July 31, 2023: Life
https://read.qxmd.com/read/37621406/a-pilot-study-of-neoadjuvant-nivolumab-ipilimumab-and-intralesional-oncolytic-virotherapy-for-her2-negative-breast-cancer
#13
JOURNAL ARTICLE
Vina P Nguyen, Katie M Campbell, Theodore S Nowicki, Nila Elumalai, Egmidio Medina, Ignacio Baselga-Carretero, Maggie L DiNome, Helena R Chang, Denise K Oseguera, Antoni Ribas, John A Glaspy
PURPOSE: Neoadjuvant combination immune checkpoint blockade and intralesional oncolytic virotherapy have the potential to activate antitumor responses in patients with breast cancer. EXPERIMENTAL DESIGN: Eligibility for this pilot phase I trial included patients with localized HER2-negative breast cancer who received systemic nivolumab and ipilimumab and intratumor talimogene laherparepvec (T-VEC; NCT04185311). The primary objective was to evaluate the safety and adverse event profile of immunotherapy combined with T-VEC in patients with localized, HER2-negative breast cancer...
August 2023: Cancer Res Commun
https://read.qxmd.com/read/37578289/clinical-updates-in-neoadjuvant-immunotherapy-for-melanoma-before-surgery
#14
REVIEW
Mariam Saad, Ella Castellano, Ahmad A Tarhini
INTRODUCTION: Locoregionally advanced melanoma represents a large group of high-risk melanoma patients at presentation and poses major challenges in relation to management and the risks of relapse and death. AREAS COVERED: Melanoma systemic therapy has undergone substantial advancements with the advent of immune checkpoint inhibitors and molecularly targeted therapies, which have been translated to the neoadjuvant setting for the management of locoregionally advanced disease...
August 14, 2023: Expert Review of Clinical Immunology
https://read.qxmd.com/read/37491263/oncolytic-virotherapy-evolved-into-the-fourth-generation-as-tumor-immunotherapy
#15
REVIEW
Xianwang Wang, Yihua Shen, Xingxia Wan, Xiaoqing Hu, Wen-Qi Cai, Zijun Wu, Qiang Xin, Xiaoqing Liu, Jingang Gui, Hong-Yi Xin, Hong-Wu Xin
BACKGROUND: Oncolytic virotherapy (OVT) is a promising anti-tumor modality that utilizes oncolytic viruses (OVs) to preferentially attack cancers rather than normal tissues. With the understanding particularly in the characteristics of viruses and tumor cells, numerous innovative OVs have been engineered to conquer cancers, such as Talimogene Laherparepvec (T-VEC) and tasadenoturev (DNX-2401). However, the therapeutic safety and efficacy must be further optimized and balanced to ensure the superior safe and efficient OVT in clinics, and reasonable combination therapy strategies are also important challenges worthy to be explored...
July 25, 2023: Journal of Translational Medicine
https://read.qxmd.com/read/37440883/development-and-application-of-oncolytic-viruses-as-the-nemesis-of-tumor-cells
#16
REVIEW
Xiao Zhu, Chenyang Fan, Zhuolong Xiong, Mingwei Chen, Zesong Li, Tao Tao, Xiuqing Liu
Viruses and tumors are two pathologies that negatively impact human health, but what occurs when a virus encounters a tumor? A global consensus among cancer patients suggests that surgical resection, chemotherapy, radiotherapy, and other methods are the primary means to combat cancer. However, with the innovation and development of biomedical technology, tumor biotherapy (immunotherapy, molecular targeted therapy, gene therapy, oncolytic virus therapy, etc.) has emerged as an alternative treatment for malignant tumors...
2023: Frontiers in Microbiology
https://read.qxmd.com/read/37383323/use-of-talimogene-laherparepvec-to-treat-cutaneous-squamous-cell-carcinoma-in-a-renal-transplant-patient
#17
Max Miller, Nancy H Kim, Maya K Thosani, Justin C Moser
A 66-year-old female with a history of two renal transplants due to recurrent thrombotic thrombocytopenic purpura presented to clinic with multiple lesions identified to be non-metastatic cutaneous squamous cell carcinoma (CSCC). The patient previously underwent multiple Mohs procedures and radiation therapy treatment but continued to develop CSCC lesions with increasing frequency. After discussing multiple treatment options, it was elected to pursue treatment with Talimogene laherparepvec (T-VEC) given the systemic immune responses it can cause, with low theoretical risk of graft rejection...
2023: Case Reports in Dermatology
https://read.qxmd.com/read/37321663/intratumoral-pan-erbb-targeted-car-t-for-head-and-neck-squamous-cell-carcinoma-interim-analysis-of-the-t4-immunotherapy-study
#18
JOURNAL ARTICLE
Sophie Papa, Antonella Adami, Michael Metoudi, Richard Beatson, Molly Sarah George, Daniela Achkova, Evangelia Williams, Sefina Arif, Fiona Reid, Maria Elstad, Nicholas Beckley-Hoelscher, Abdel Douri, Marc Delord, Mike Lyne, Dharshene Shivapatham, Christopher Fisher, Andrew Hope, Sakina Gooljar, Arindam Mitra, Linda Gomm, Cienne Morton, Rhonda Henley-Smith, Selvam Thavaraj, Alice Santambrogio, Cynthia Andoniadou, Sarah Allen, Victoria Gibson, Gary J R Cook, Ana C Parente-Pereira, David M Davies, Farzin Farzaneh, Anna Schurich, Teresa Guerrero-Urbano, Jean-Pierre Jeannon, James Spicer, John Maher
BACKGROUND: Locally advanced/recurrent head and neck squamous cell carcinoma (HNSCC) is associated with significant morbidity and mortality. To target upregulated ErbB dimer expression in this cancer, we developed an autologous CD28-based chimeric antigen receptor T-cell (CAR-T) approach named T4 immunotherapy. Patient-derived T-cells are engineered by retroviral transduction to coexpress a panErbB-specific CAR called T1E28ζ and an IL-4-responsive chimeric cytokine receptor, 4αβ, which allows IL-4-mediated enrichment of transduced cells during manufacture...
June 2023: Journal for Immunotherapy of Cancer
https://read.qxmd.com/read/37298206/human-monocytes-are-suitable-carriers-for-the-delivery-of-oncolytic-herpes-simplex-virus-type-1-in-vitro-and-in-a-chicken-embryo-chorioallantoic-membrane-model-of-cancer
#19
JOURNAL ARTICLE
Alberto Reale, Lea Krutzke, Massimiliano Cadamuro, Adriana Vitiello, Jens von Einem, Stefan Kochanek, Giorgio Palù, Cristina Parolin, Arianna Calistri
Oncolytic viruses (OVs) are promising therapeutics for tumors with a poor prognosis. An OV based on herpes simplex virus type 1 (oHSV-1), talimogene laherparepvec (T-VEC), has been recently approved by the Food and Drug Administration (FDA) and by the European Medicines Agency (EMA) for the treatment of unresectable melanoma. T-VEC, like most OVs, is administered via intratumoral injection, underlining the unresolved problem of the systemic delivery of the oncolytic agent for the treatment of metastases and deep-seated tumors...
May 25, 2023: International Journal of Molecular Sciences
https://read.qxmd.com/read/37292376/a-phase-1-first-in-child-multicenter-study-to-evaluate-the-safety-and-efficacy-of-the-oncolytic-herpes-virus-talimogene-laherparepvec-in-pediatric-patients-with-advanced-solid-tumors
#20
JOURNAL ARTICLE
Lucas Moreno, Pierre Teira, James M Croop, Nicolas U Gerber, Nicolas André, Isabelle Aerts, Luis Gros Subias, Bram De Wilde, Francisco Bautista, Brian Turpin, Srinivasa Kunduri, Ali Hamidi, Tatiana Lawrence, Keri A Streby
BACKGROUND: The survival rates for pediatric patients with relapsed and refractory tumors are poor. Successful treatment strategies are currently lacking and there remains an unmet need for novel therapies for these patients. We report here the results of a phase 1 study of talimogene laherparepvec (T-VEC) and explore the safety of this oncolytic immunotherapy for the treatment of pediatric patients with advanced non-central nervous system tumors. METHODS: T-VEC was delivered by intralesional injection at 106 plaque-forming units (PFU)/ml on the first day, followed by 108 PFU/ml on the first day of week 4 and every 2 weeks thereafter...
2023: Frontiers in Pediatrics
keyword
keyword
109513
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.